Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments

BACKGROUND: The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol...

Descripción completa

Detalles Bibliográficos
Autores principales: Massa, Federico, Franciotta, Diego, Grisanti, Stefano, Roccatagliata, Luca, Morbelli, Silvia, Beltramini, Sabrina, Uccelli, Antonio, Schenone, Angelo, Benedetti, Luana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616745/
https://www.ncbi.nlm.nih.gov/pubmed/35953578
http://dx.doi.org/10.1007/s10072-022-06313-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616745/
https://www.ncbi.nlm.nih.gov/pubmed/35953578
http://dx.doi.org/10.1007/s10072-022-06313-3

Ejemplares similares